Development of In Vitro-In Vivo Correlation/Relationship Modeling Approaches for Immediate Release Formulations Using Compartmental Dynamic Dissolution Data from "Golem": A Novel Apparatus
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
26120580
PubMed Central
PMC4450231
DOI
10.1155/2015/328628
Knihovny.cz E-zdroje
- MeSH
- atorvastatin chemie terapeutické užití MeSH
- chemie farmaceutická MeSH
- gastrointestinální trakt účinky léků fyziologie MeSH
- lidé MeSH
- tenké střevo účinky léků MeSH
- uvolňování léčiv * MeSH
- zdravotnické prostředky MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- atorvastatin MeSH
Different batches of atorvastatin, represented by two immediate release formulation designs, were studied using a novel dynamic dissolution apparatus, simulating stomach and small intestine. A universal dissolution method was employed which simulated the physiology of human gastrointestinal tract, including the precise chyme transit behavior and biorelevant conditions. The multicompartmental dissolution data allowed direct observation and qualitative discrimination of the differences resulting from highly pH dependent dissolution behavior of the tested batches. Further evaluation of results was performed using IVIVC/IVIVR development. While satisfactory correlation could not be achieved using a conventional deconvolution based-model, promising results were obtained through the use of a nonconventional approach exploiting the complex compartmental dissolution data.
Zobrazit více v PubMed
McAllister M. Dynamic dissolution: a step closer to predictive dissolution testing? Molecular Pharmaceutics. 2010;7(5):1374–1387. doi: 10.1021/mp1001203. PubMed DOI
Culen M., Dohnal J. Advances in dissolution instrumentation and their practical applications. Drug Development and Industrial Pharmacy. 2013 PubMed
Souliman S., Beyssac E., Cardot J.-M., Denis S., Alric M. Investigation of the biopharmaceutical behavior of theophylline hydrophilic matrix tablets using usp methods and an artificial digestive system. Drug Development and Industrial Pharmacy. 2007;33(4):475–483. doi: 10.1080/03639040601128654. PubMed DOI
Amidon G. L., Lennernas H., Shah V. P., Crison J. R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical Research. 1995;12(3):413–420. doi: 10.1023/A:1016212804288. PubMed DOI
Bárta J., Mudra P., Pešek V., et al. Digestive tract simulator. 2011, http://patentscope.wipo.int/search/en/WO2011069472.
Culen M., Rezacova A., Jampilek J., Dohnal J. Designing a dynamic dissolution method: a review of instrumental options and corresponding physiology of stomach and small intestine. Journal of Pharmaceutical Sciences. 2013;102(9):2995–3017. doi: 10.1002/jps.23494. PubMed DOI
Watanabe T., Kusuhara H., Maeda K., et al. Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. Drug Metabolism and Disposition. 2010;38(2):215–222. doi: 10.1124/dmd.109.030254. PubMed DOI
Ishigami M., Honda T., Takasaki W., et al. A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metabolism and Disposition. 2001;29(3):282–288. PubMed
Jacobsen W., Kuhn B., Soldner A., et al. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metabolism and Disposition. 2000;28(11):1369–1378. PubMed
Kim J.-S., Kim M.-S., Park H. J., Jin S.-J., Lee S., Hwang S.-J. Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process. International Journal of Pharmaceutics. 2008;359(1-2):211–219. doi: 10.1016/j.ijpharm.2008.04.006. PubMed DOI
Mendyk A. CRAN—Package Rivivc. http://cran.r-project.org/web/packages/Rivivc/index.html.
Jamei M., Marciniak S., Edwards D., et al. The simcyp population based simulator: architecture, implementation, and quality assurance. Silico Pharmacology. 2013;1(1):p. 9. PubMed PMC
Poulin P., Theil F.-P. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. Journal of Pharmaceutical Sciences. 2002;91(1):129–156. doi: 10.1002/jps.10005. PubMed DOI
Lennernäs H., Aarons L., Augustijns P., et al. Oral biopharmaceutics tools—time for a new initiative—an introduction to the IMI project OrBiTo. European Journal of Pharmaceutical Sciences. 2014;16(57):292–299. doi: 10.1016/j.ejps.2013.10.012. PubMed DOI
FDA. Guidance for Industry: Extended Release Oral Dosage Forms: Development, Evaluation, and Application of in Vitro/in Vivo Correlations. 1997. PubMed
Lennernäs H. Clinical pharmacokinetics of atorvastatin. Clinical Pharmacokinetics. 2003;42(13):1141–1160. PubMed